During the reporting period, the net cash flow from operating activities was RMB 65,565,438+RMB 07,568,5438+RMB 02, and the net assets attributable to shareholders of listed companies at the end of 2020 were RMB 724,026,438+RMB 0,493.38.
In February 2020, the operating income was 1- 1.90632 million yuan, up 6.25% year-on-year, with an increase of 42.2752 million yuan. Due to the market demand and the company's strategic adjustment factors, the sales of intermediates increased by 92.325438 million yuan; API revenue decreased by 565,438+0,433, 700 yuan; The income of fine chemicals increased by 8,654.38+0,654.38+0,730 yuan; The trade income of general chemical products decreased by 6,993,600 yuan.
In 20201-65438+February, the monthly net profit was RMB 648,654,338+0.8 million, an increase of RMB 654,338+0.00% year-on-year. The main reason for the increase in net profit is the increase in income.
The financial expenses during the period were 15,167,971.08 yuan, compared with14,994,094.1yuan in the same period of last year, an increase of/kloc-0. During the period, the investment income was 856,598.89 yuan, compared with 75,483.40 yuan in the same period of last year, up by 65,438+0,034.82% year-on-year, mainly because it took a long time to purchase wealth management products and the investment income was large.
According to Digby's data. Hemujia medicine belongs to the pharmaceutical manufacturing industry. The main business is the research and development, production and sales of pharmaceutical intermediates and cephalosporin APIs, supplemented by the research and development, production and sales of chemical products trade and fine chemical products.
This article comes from Digging Shell Network.